Seven Things To Know About Medicare Part D And Prior Authorization
Prior authorization is becoming a bigger issue with Medicare Part D drug plans. getty
Over the last several years, prior authorization has become a hot topic. Nearly all those who have Medicare Advantage plans must deal with it for medical services. You've seen the news stories about the denials and their impact on care. A new rule that will be implemented fully by 2027 is supposed to help resolve the issues but time will tell.
Now, in 2025, a new wrinkle – prior authorization problems with Part D prescription drugs. Drug plans have required authorization of select medications since the program started in 2006. However, I have received several calls and emails about problems getting approval, a new phenomenon for me this year.
Because of the Inflation Reduction Act and the $2,000 cap on out-of-pocket drug costs, Part D drug plans are picking up a larger share of the costs. So, they want to make sure they pay only when it is appropriate. Prior authorization is one way to ensure that. Since more enrollees seem to be dealing with this issue, here are some things to know.
The top-three reasons on my list all connect to reducing the costs a plan may have to cover. There is a lower-cost alternative drug for the situation.
Part A, hospital insurance, or Part B, medical insurance, should cover this drug, not the Part D plan.
This drug being prescribed is not for a medically accepted indication. Part D generally doesn't cover a drug for off-label use, unless it's medically necessary, which may not be easy to prove.
Other reasons for authorization can include: Drugs with special monitoring requirements
Certain dosages or forms of a medication
Controlled substances, and
Drugs that may interact with other drugs.
A man shared with me his issue with prior authorization. His 'rep' found a new plan that would save him several hundred dollars on premiums. However, now he cannot get a Tier 5 specialty drug approved. He is mad at his rep for recommending that plan.
Each drug plan identifies the drugs that will be subject to authorization. It's very possible that costly Tier 4, non-preferred brand, and Tier 5 drugs will require it. After a quick check, I discovered that every plan in the man's area required authorization for his specialty medication so there was no escaping it.
I have also seen many Tier 3, preferred brand, and even an occasional Tier 2, generic drug, requiring authorization. Every drug plan has its own procedure and form.
Another man reported that he had been waiting almost two weeks for approval. A drug plan representative told him they could not approve the request because his physician submitted the wrong form.
The insurers' forms I reviewed range from one to nine pages with some similar questions but enough variation to make using the right form important.
You can find the right form by searching 'Part D prior authorization form for (name of drug plan).' Calling the plan is another option but trying to get through to the person who knows something about authorization could be difficult and time-consuming. The prescriber or the drug plan member can submit the request.
I heard from a woman who ran out of her medication. When she went to get the drug on a Sunday, she was shocked to discover the new plan requires authorization. So she asked the pharmacist to do this.
Pharmacists know the medications but usually are not the prescribers. The physician or healthcare practitioner who knows the rationale for a particular drug would be the best one to handle authorization. But, in a pinch, the plan member has the ability to do this with a supporting statement from the physician. The form must be completed, in its entirety, with information to support the need for the medication.
When preparing the authorization form: Follow the instructions.
Include a pertinent diagnosis and relevant history, symptoms, or findings.
Explain why other drugs (especially less costly ones) likely won't work (could have adverse outcomes or not be as effective). The process can take time.
The same woman thought the pharmacist could get authorization simply by calling the drug plan.
Even if the pharmacist could connect with the right person during a weekend phone call, it's very unlikely that the plan would grant authorization. After receiving the form and supporting documentation, the plan has to notify the prescriber and enrollee withing 72 hours for a standard determination and 24 hours for an expedited one. Being proactive may help prevent some of the problems
Obtaining prior authorization is generally a physician or prescriber issue. However, when able, Part D enrollees should take some responsibility to smooth out the process as much as possible.
Here's a list of some things you can do. Know whether any of your drugs are subject to authorization. Find that information in the plan's documents or the Medicare Plan Finder.
Do not wait until the last minute to deal with this.
Discuss the situation with your physician. If possible, provide a copy of the plan's form.
Watch for notification from the drug plan.
Review other plans during Open Enrollment. You might find one that doesn't require authorization. But then, check the trade-offs – how this plan works and how much you might pay.
Remember, of course, that determining and obtaining prior authorization when necessary is generally your provider's responsibility. But you obviously have skin in the game. So, pay attention and never hesitate to ask your provider if there's anything you can do to facilitate the process.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
Fast Five Quiz: Alcohol Use Disorder
Alcohol use disorder remains a significant public health challenge in the United States, affecting more than 29 million individuals and contributing to more than 140,000 deaths each year. Despite its high prevalence and devastating health consequences, alcohol use disorder often goes underdiagnosed and undertreated. A widely accepted heuristic framework conceptualizes alcohol use disorder as a 3-stage cycle, binge/intoxication, withdrawal/negative affect, and preoccupation/anticipation, offering clinicians a lens through which to understand its complex neurobiological underpinnings and diverse clinical presentations. Although effective behavioral therapies and several US Food and Drug Administration-approved medications are available for the treatment of alcohol use disorder, these interventions remain markedly underused, contributing to a substantial treatment gap. How much do you know about alcohol misuse and alcohol use disorder? Test your knowledge with this quick quiz. Alcohol misuse in alcohol use disorder can vary, from a pattern of intermittent episodes of binge drinking, to a pattern of prolonged heavy drinking over longer periods of time, to a continual drinking pattern due to fear of alcohol withdrawal. A heavy drinking day is defined as consuming 4 or more drinks for females and 5 or more drinks for males in a single day. In the United States, a standard drink is defined as 12 oz of beer, 5 oz of wine, and 1.5 oz of a distilled beverage. This definition helps identify patterns of alcohol misuse that might indicate alcohol use disorder. Learn more about alcoholism guidelines. Alcohol use disorder is more common in males, although the gap is narrowing. Although males are more likely to engage in frequent and heavy consumption, have a greater consumption of spirits, and experience higher rates of alcohol use mortality, females are at greater risk for certain health complications from alcohol, such as liver damage and experiencing higher blood alcohol concentrations at the same level of intake. Learn more about alcoholism presentation. The most frequent central nervous system consequence of persistent alcohol consumption is alcoholic cerebellar degeneration. This condition results from alcohol toxicity leading to damage of the cerebellum, the brain area responsible for coordination and balance. It commonly presents with gait instability, and balance problems, affecting 10%-25% of individuals with chronic alcohol use. Wernicke's encephalopathy is an acute, reversible condition caused by thiamine deficiency; it is not the most frequent long-term central nervous system consequence of alcohol consumption. Korsakoff syndrome is a chronic neuropsychiatric disorder that often follows untreated Wernicke's encephalopathy and is caused by malnutrition in combination with prolonged drinking. Although chronic alcohol use can lead to alcohol-related dementia, it occurs less frequently than alcoholic cerebellar degeneration. Learn more about Wernicke-Korsakoff syndrome. Alcoholic polyneuropathy, caused by prolonged alcohol use and often associated with nutritional deficiencies like thiamine deficiency, typically presents as a symmetrical sensory neuropathy. Females have a greater rate of alcoholic polyneuropathy. The most common symptoms of alcoholic polyneuropathy are ataxia, pain, and paresthesia. Other frequent symptoms include burning pain in the arms, soles of the feet and toes, and cramping in the calves and hands. Skin alterations do occur in alcoholic polyneuropathy, but they are considered secondary or less common symptoms compared with the hallmark neurological signs. The muscle weakness seen in alcoholic polyneuropathy primarily affects distal muscles, like the feet and hands. Hair loss can happen as a minor trophic change, but it is not a defining or common symptom of alcoholic polyneuropathy. Learn more about alcoholic neuropathy. Benzodiazepines are the recommended class of medication for treating alcohol withdrawal syndrome because they are effective in preventing severe complications of alcohol withdrawal syndrome, such as seizures and delirium tremens, and are considered the criterion standard treatment due to their fast onset, long duration, and safety profile. Selective serotonin reuptake inhibitors do not target the GABAergic or glutamatergic systems involved in alcohol withdrawal syndrome, making them ineffective for managing withdrawal symptoms. Beta-blockers can help control some autonomic symptoms like tremors or tachycardia but do not prevent seizures or delirium tremens, so they are not appropriate as primary treatment. N-methyl-D-aspartate receptor antagonists can modulate glutamate activity but lack enough evidence to be first-line therapy for alcohol withdrawal syndrome. Learn more about alcohol withdrawal syndrome.
Yahoo
2 hours ago
- Yahoo
OrsoBio to Present Preclinical Data on Mitochondrial Protonophore Portfolio in Models of Obesity at the American Diabetes Association's 85th Scientific Sessions
Data demonstrate the potential of TLC-6740 and TLC-1180 to induce weight loss while preserving lean mass, as monotherapy and in combination with an incretin, in obese mice MENLO PARK, Calif., June 20, 2025--(BUSINESS WIRE)--OrsoBio, Inc. ("OrsoBio" or "the Company"), a clinical-stage biopharmaceutical company developing treatments for obesity and obesity-associated disorders, today announced new preclinical data being presented at the 85th Scientific Sessions of the American Diabetes Association (ADA) being held June 20-23, 2025, in Chicago, Ill. The Company will present three abstracts highlighting the efficacy of its mitochondrial protonophores to induce weight loss and provide glycemic benefits while preserving lean mass in diet-induced obese (DIO) mice. The studies demonstrate the potential of TLC-6740 and TLC-1180—as monotherapy and in combination with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide—for both the induction and maintenance of weight loss following incretin treatment. "The mechanism of our mitochondrial protonophores to increase energy expenditure complements that of incretins to enhance and sustain weight loss and provide additive metabolic benefits," said Mani Subramanian, MD, PhD, Chief Executive Officer of OrsoBio. "These preclinical findings mark an important step in fulfilling our mission to develop innovative, effective, oral therapies for obesity that preserve muscle and support cardiometabolic health." OrsoBio is advancing a pipeline of novel therapies targeting obesity through mechanistically distinct and complementary approaches. The Company's lead candidates include TLC-6740 and TLC-1180, both mitochondrial protonophores that promote weight loss by increasing energy expenditure. In addition, OrsoBio is developing TLC-3595, a selective inhibitor of acetyl-CoA carboxylase 2 (ACC2), designed to enhance fat oxidation. "GLP-1 receptor agonists have transformed obesity treatment but are limited by gastrointestinal side effects and loss of muscle mass," said Rob Myers, MD, Chief Medical Officer of OrsoBio. "Our preclinical data show that our mitochondrial protonophores drive sustained, fat-selective weight loss and metabolic benefits when combined with or sequenced after GLP-1 receptor agonists. These findings support our ongoing Phase 1b study of TLC-6740 in combination with tirzepatide (NCT05822544)." Poster information: Sequential Combination of the Mitochondrial Protonophore TLC-6740 With Semaglutide Normalizes Body Weight and Preserves Lean Mass in DIO MiceAbstract #1687-P Poster Session: Monday, June 23, 2025 (12:30 - 1:30 p.m. CT)This preclinical study assessed TLC-6740 alone, in combination with low-dose semaglutide (sequential combination), and as maintenance therapy following semaglutide discontinuation in DIO mice. The sequential combination of TLC-6740 with low-dose semaglutide produced superior body weight and fat mass loss, and improved glycemic parameters compared with TLC-6740 alone and high-dose semaglutide. Initiating TLC-6740 after semaglutide discontinuation maintained body weight and fat mass loss, and glycemic benefits. These findings support evaluation of TLC-6740 in combination with incretins in people living with obesity; a 24-week combination study of TLC-6740 with tirzepatide is ongoing (NCT05822544). De Novo or Sequential Combination of the Mitochondrial Protonophore TLC-1180 With Semaglutide Improves Weight Loss and Preserves Lean Mass in DIO MiceAbstract #1694-P Poster Session: Monday, June 23, 2025 (12:30 - 1:30 p.m. CT)This preclinical study evaluated the effects of TLC-1180 alone, in combination with semaglutide, and as a maintenance treatment following semaglutide discontinuation in DIO mice. As monotherapy, TLC-1180 demonstrated body weight and fat mass loss and preserved lean mass. Body weight and fat mass loss were amplified, and lean mass was preserved with TLC-1180 in combination with semaglutide. These benefits persisted when TLC-1180 was used as a maintenance treatment after semaglutide discontinuation. These data highlight the potential of TLC-1180 as monotherapy, in combination with incretins, or as maintenance therapy post incretin discontinuation in people living with obesity. Novel Combination of a Mitochondrial Protonophore and an Acetyl-CoA Carboxylase 2 (ACC2) Inhibitor Causes Weight Loss and Preserves Lean Mass in Obese MiceAbstract #1686-P Poster Session: Monday, June 23, 2025 (12:30 - 1:30 p.m. CT)This preclinical study evaluated the effects of the mitochondrial protonophore, TLC-1180, and the ACC2 inhibitor, TLC-3595—as monotherapy and in combination—and semaglutide in DIO mice. TLC-3595 dose dependently reduced body weight, fat mass, and liver biochemistry while preserving lean mass in DIO mice. A combination of TLC-3595 with TLC-1180 had similar weight loss efficacy to semaglutide, but preserved lean mass. Taken together, these data suggest that the novel, all-oral, non-incretin combination of TLC-3595 and TLC-1180 may cause similar weight loss to incretins and may afford additional advantages, including improved weight loss quality and/or tolerability (e.g., reduced incidence of gastrointestinal adverse events). About TLC-6740 TLC-6740 is a novel, oral, liver-targeted mitochondrial protonophore in development for the treatment of obesity and obesity-associated diseases, including diabetes and MASH. Based on active hepatic uptake and mitochondrial protonophore activity, TLC-6740 increases energy expenditure in hepatocytes, and is expected to have broad, systemic metabolic and cardiovascular benefits, including weight loss, improved insulin sensitivity, and as a treatment for MASH, and dyslipidemia. TLC-6740 is currently being evaluated in a Phase 1b clinical trial, as monotherapy and in combination with tirzepatide, in patients living with obesity (NCT05822544). About TLC-1180 TLC-1180 is a novel, potent, long-acting mitochondrial protonophore that has been shown to increase energy expenditure in mice with diet-induced obesity (DIO). In preclinical studies of DIO mice, TLC-1180 induced weight loss, improved glucose control, and enhanced the efficacy of GLP-1 receptor agonists, both as a single agent and in combination with incretins. TLC-1180 is currently completing IND-enabling studies and a first-in-human study is expected to initiate in 2025. About TLC-3595 TLC-3595 is a novel and selective ACC2 inhibitor designed to treat obesity and type 2 diabetes by increasing fatty acid oxidation (FAO), reducing ectopic lipid accumulation, and improving insulin sensitivity in skeletal muscle and liver. The compound may also have potential as a treatment for other conditions characterized by impaired FAO, including heart failure with preserved ejection fraction (HFpEF) and metabolic dysfunction-associated steatohepatitis (MASH). About OrsoBio, Inc. OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat obesity and obesity-associated disorders, including type 2 diabetes, MASH, and severe dyslipidemias. OrsoBio currently has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism. For more information, please visit View source version on Contacts Media Contact Gwen GordonGwen@ Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
Experts issue warning over dangerous new insect species spreading across US: 'Managing them is not easy'
An invasive tick species from Asia is quickly multiplying across the eastern United States, and according to Patch, it's prompting concern from environmental officials. The Asian longhorned tick, first identified in the U.S. in 2017, has now been found in at least 17 states and is spreading particularly fast in southeastern Pennsylvania, where cases have surged by 150% over the last five years. Unlike most ticks, the Asian longhorned tick doesn't need a mate to reproduce. One female can lay up to 3,000 eggs, resulting in infestations so dense that wildlife officials have found hundreds of ticks on a single animal. "Managing them is not easy because of how numerous they are and how easily they can come back," Risa Pesapane, a preventive medicine professor at Ohio State University, said, per Patch. Luckily, there's no strong evidence linking these ticks to Lyme disease. However, their ability to transmit other illnesses, including a cattle disease called Theileria orientalis that causes severe anemia and fever, poses an urgent threat to food supply chains and native animal populations. Their rapid spread also puts pressure on local ecosystems. Asian longhorned ticks feed on a wide range of animals, from deer and raccoons to dogs, cats, cattle, and even squirrels and skunks. With their capacity for rapid growth and adaptability to mild, humid conditions, experts warn that they could eventually populate much of the eastern U.S. and parts of the West Coast. Invasions like this destroy biodiversity by outcompeting native tick species and disrupting predator-prey relationships that keep nature in balance. In a world already struggling with rising temperatures and shrinking habitats, the introduction of yet another aggressive species threatens to worsen existing issues. According to Patch, experts say prevention and early action are key. Pesticides can work, but only when applied directly. Even then, ticks often bounce back. The best approach is to keep pastures mowed, regularly check pets and livestock, and report sightings to local health officials. If you find a tick on you, store it in rubbing alcohol and contact your doctor or county health office. For pets and livestock, get in touch with your vet immediately. Perhaps most importantly, support efforts to protect native ecosystems. The more resilient our local wildlife and natural habitats are, the harder it is for invasive species to take hold. Should the government be able to control how we heat our homes? Definitely Only if it saves money I'm not sure No way Click your choice to see results and speak your mind. Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.
